- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07941310
A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer
A Phase 2, Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Erlotinib in Patients With EGFR-Amplified Metastatic Colorectal Cancer Who Have Failed or Are Not Eligible for Oxaliplatin- and Irinotecan-Based Chemotherapy
This phase II, open-label, single-arm clinical trial is designed to evaluate the efficacy and safety of a combination therapy with bevacizumab and erlotinib as a salvage treatment in patients with metastatic colorectal cancer who have failed or are intolerant to standard oxaliplatin- and irinotecan-based chemotherapy, and whose tumors harbor an EGFR copy number gain of 4 or higher confirmed by NGS testing. The primary objective is to evaluate progression-free survival (PFS), and secondary objectives include objective response rate (ORR), overall survival (OS), disease control rate (DCR), safety, and quality of life.
연구 개요
상세 설명
This study investigates the clinical benefit of combining an anti-VEGF agent (bevacizumab) with an EGFR tyrosine kinase inhibitor (erlotinib) in refractory metastatic colorectal cancer with EGFR amplification. Eligible patients will receive bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral erlotinib at 150 mg. Tumor assessments will be conducted periodically using RECIST version 1.1 to determine clinical outcomes, and toxicities will be graded according to NCI CTCAE version 5.0.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Soohyeon Lee, MD, PhD
- 이메일: soohyeon_lee@korea.ac.kr
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Histologically or cytologically proven metastatic/recurrent colorectal cancer who have failed or are intolerant to standard chemotherapy based on oxaliplatin and irinotecan (and if RAS wild-type, an anti-EGFR therapy).
-
EGFR copy number gain ≥ 4 confirmed by NGS testing performed at the participating institution.
-
Measurable disease per RECIST version 1.1 (measurable lesions are not mandatory for study entry).
-
Age ≥ 19 years.
-
ECOG performance status 0-2.
-
Adequate bone marrow and organ function:
- Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L
- Hemoglobin (Hgb) ≥ 9.0 g/dL
- Platelet count ≥ 75 x 10^9/L
- Serum creatinine ≤ 1.5 x ULN or creatinine clearance > 30 mL/min
- Total bilirubin ≤ 2.0 x ULN (subjects with biliary obstruction are eligible if criteria are met after appropriate biliary drainage)
- AST and ALT ≤ 3 x ULN (or ≤ 5 x ULN if liver metastases are present)
-
Adequate cardiac function: QTc ≤ 480 msec (if QTc > 480 msec, average QTc < 480 msec in triplicate measurements).
-
Ability to swallow oral medication.
-
Negative serum β-HCG pregnancy test within 14 days prior to study drug administration for female patients of childbearing potential.
-
Agreement to use appropriate contraception methods as outlined in the protocol.
-
Life expectancy ≥ 3 months.
-
Signed and dated informed consent prior to any study-related procedures.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Prior history of combination therapy with an EGFR tyrosine kinase inhibitor and anti-VEGF blockade.
- Known hypersensitivity to the study drug components.
- Cytotoxic chemotherapy within 14 days, investigational drugs within 2 weeks or 5 half-lives, or monoclonal antibody therapy within 4 weeks prior to study entry.
- Uncontrolled severe infection.
- Severe medical or psychiatric conditions including active cardiac disease, uncontrolled hypertension, significant arrhythmias, or conditions prolonging QTc.
- Active central nervous system (CNS) metastases (unless radiologically stable, asymptomatic, and off steroids for at least 4 weeks; leptomeningeal disease is excluded).
- History of another primary malignancy (except adequately treated non-melanoma skin cancer, superficial cervical carcinoma, stage 1 bladder cancer, completely resected thyroid cancer, or other solid tumors with no evidence of recurrence for at least 36 months).
- Persistence of toxicities from prior anticancer therapy > Grade 1 (except alopecia).
- Extensive radiotherapy to the bone marrow within 4 weeks or limited radiotherapy within 2 weeks prior to study entry.
- Major surgery within 4 weeks prior to study entry or unrecovered from surgical side effects.
- Thrombotic or thromboembolic events within 6 months.
- History or evidence of bleeding disorders.
- Therapeutic use of maximum dose anticoagulants.
- Unhealed wounds, acute ulcers, or bone fractures.
- Abdominal fistula, gastrointestinal perforation, or active GI bleeding within 6 months.
- Urine dipstick protein ≥ 2+ with 24-hour urine protein > 1g.
- History or pathological findings of major GI surgery that may impair oral absorption.
- Evidence of active infection including Hepatitis B, Hepatitis C, or HIV (subjects with controlled or inactive HBV/HCV under specific protocol criteria are permitted).
- Conditions or diseases deemed by the investigator to contraindicate study participation.
- Medical, psychological, cognitive, or other conditions that impair the subject's ability to understand, consent, or comply with protocol procedures.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Bevacizumab plus Erlotinib
Participants will receive Bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral Erlotinib at 150 mg. |
Administered at 7.5 mg/kg intravenously every 3 weeks.
다른 이름들:
Administered at 150 mg orally daily.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival (PFS)
기간: From the first dose of study treatment until disease progression or death, assessed up to 12 months
|
PFS is calculated from the date of the first administration of the study drug to the date of documented disease progression or death from any cause. |
From the first dose of study treatment until disease progression or death, assessed up to 12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Response Rate (ORR)
기간: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
|
Proportion of patients who achieve a Complete Response (CR) or Partial Response (PR) evaluated using RECIST version 1.1. |
Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
|
|
Overall Survival (OS)
기간: From the first dose of study treatment until death, assessed up to 1 year of survival follow-up
|
OS is calculated from the date of the first administration of the study drug to the date of death from any cause or the last follow-up date |
From the first dose of study treatment until death, assessed up to 1 year of survival follow-up
|
|
Disease Control Rate (DCR)
기간: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
|
Proportion of patients who achieve CR, PR, or stable disease (SD) maintained for at least 6 weeks after study drug administration |
Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
|
|
Duration of Response (DOR)
기간: From initial response until documented disease progression, assessed up to approximately 12 months
|
Calculated from the time initial response (CR or PR) is documented until the date of progressive disease |
From initial response until documented disease progression, assessed up to approximately 12 months
|
|
Time to Response (TTR)
기간: From the first dose of study treatment until the first documented response, assessed up to approximately 12 months
|
Calculated from the first dose of study treatment to the date of initial response (CR or PR) |
From the first dose of study treatment until the first documented response, assessed up to approximately 12 months
|
|
Safety and Tolerability
기간: From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months
|
Evaluated by type, frequency, and severity of adverse events graded according to NCI CTCAE version 5.0 |
From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months
|
|
Quality of Life (QoL) EORTC QLQ-C30
기간: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months
|
Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) |
Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months
|
|
Quality of Life (QoL) CR26
기간: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months
|
Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (CR26) |
Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- COBET
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Yes. De-identified individual participant data underlying the results reported in this article, after de-identification, will be shared beginning 3 months and ending 5 years following article publication to researchers who provide a methodologically sound proposal. Proposals should be directed to the corresponding author. Data getters will be required to sign a data access agreement.
IPD 공유 기간
Beginning 3 months and ending 5 years following article publication.
IPD 공유 액세스 기준
De-identified individual participant data will be shared with researchers who provide a methodologically sound proposal to achieve the aims of the approved proposal. Proposals should be directed to the corresponding author. Data requesters will be required to sign a data access agreement.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .